Treatment progress of mantle cell lymphoma
10.3760/cma.j.issn.1009-9921.2018.01.004
- VernacularTitle:套细胞淋巴瘤治疗研究进展
- Author:
Ruolan ZENG
1
;
Yajun LI
;
Hui ZHOU
Author Information
1. 湖南省肿瘤医院 中南大学湘雅医学院附属肿瘤医院淋巴瘤血液内科
- Keywords:
Lymphoma;
mantle-cell;
Drug resistance;
Targeted therapy
- From:
Journal of Leukemia & Lymphoma
2018;27(1):12-15
- CountryChina
- Language:Chinese
-
Abstract:
Mantle cell lymphoma (MCL) is an unique B-cell non-Hodgkin lymphoma with aggressive biological behavior, high malignancy, fast progress, bad reaction to the normal treatment, short remission after the standard treatment, which is still considered as the an incurable lymphoma type. The 59th American Society of Hematology Annual Meeting covered progress of the new target exploration of MCL, the drug resistance study and the optimization of clinical trails. The paper discusses the progress of MCL treatment according to the meeting literatures.
